Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells

Medical Oncology
Chen WeiXingXu Ping

Abstract

To observe the inhibitory effect of Hypoxia inducible factor-1 antisense oligonuclecotide on growth of human hepatocellular carcinoma cells and gene expression of HIF-1, in order to seek a new gene therapy for hepatocellular carcinoma. Six Hypoxia inducible factor-1 antisense oligonuclecotides with various concentrations (0.2 micromol/l, 0.4 micromol/l, and 0.8 micromol/l) were transformed into HepG2 cells by lipofectamine reagent. 72 h after transfection, MTS assay was used to detect cellular proliferation. In addition, Hypoxia inducible factor-1 antisense oligonuclecotide2 with various concentrations (0.2, 0.4, 0.8, and 1.0 micromol/l) were transformed into HepG2 cells. About 48 h after transfection, reverse transcription-polymerase chain reaction assay and Western Blot assay were employed to detect the expression of Hypoxia inducible factor-1 gene and the synthesis of Hypoxia inducible factor-1 protein respectively. HepG2 cell growth was inhibited by 6 Hypoxia inducible factor-1 antisense oligonuclecotides at various concentrations. Among them, Hypoxia inducible factor-1 antisense oligonuclecotide2 showed the most effective inhibition ability (P < 0.01), the inhibitory rate was 89.66% at the concentration of 1.0 micromol/l. ...Continue Reading

References

Feb 22, 2001·Journal of the National Cancer Institute·M Höckel, P Vaupel
Feb 22, 2001·Journal of the National Cancer Institute·R BosE van der Wall
May 3, 2003·Cancer Cell·Selma PennacchiettiPaolo M Comoglio
Jun 5, 2003·Nature Medicine·Christopher W Pugh, Peter J Ratcliffe
Sep 18, 2003·Nature Reviews. Cancer·Gregg L Semenza
May 4, 2004·Nature Reviews. Molecular Cell Biology·Christopher J Schofield, Peter J Ratcliffe
Aug 10, 2004·International Journal of Cancer. Journal International Du Cancer·Qunzhou ZhangAnh D Le
Dec 14, 2004·The Oncologist·Louis Harrison, Kimberly Blackwell
Dec 16, 2004·International Review of Cytology·M Christiane Brahimi-Horn, Jacques Pouysségur
Apr 9, 2005·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·Peter Vaupel, Arnulf Mayer
May 21, 2005·Nature Reviews. Cancer·Martin E Gleave, Brett P Monia
Sep 16, 2005·Anti-cancer Drugs·Vladimir E Belozerov, Erwin G Van Meir
Sep 24, 2005·Current Medicinal Chemistry·T Aboul-Fadl
May 25, 2006·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Lei DingWanguang Zhang
Nov 24, 2006·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Wanguang ZhangLihua Xing

❮ Previous
Next ❯

Citations

Jul 19, 2011·Cancer Treatment Reviews·Sheng-Di WuXi-Zhong Shen
Jan 29, 2011·Hepatobiliary & Pancreatic Diseases International : HBPD INT·Tian-Qi LiuShu-Sen Zheng
Aug 8, 2014·BioMed Research International·Dongjun LuoJunhua Wu
Oct 7, 2010·The Korean Journal of Hepatology·Jin-Wook Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Fernanda Rocha Rojas AyalaFernando Augusto Soares
© 2021 Meta ULC. All rights reserved